Short-Acting Opioids Up Fracture Risk in Elderly
January 1, 2011|Endocrinology
Author and Disclosure Information
From the Annual Meeting of the American Public Health Association
The Food and Drug Administration recently removed from the U.S. market one of the short-acting opioids in this study – propoxyphene – because of an increased risk for fatal heart rhythm abnormalities associated with its use.
Dr. Miller declared having no relevant financial interests.
Document
When 90% of opioids prescribed to the elderly are short-acting, we may be putting people at unnecessary risk.
Source DR. MILLER
